

Form PTO-1449 (Modified)
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTORNEY DOCKET NO.:
10062-1APPLICATION NO.
09/227,749

INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)
(Use several sheets if necessary)APPLICANT:
Brian J. Balin, et alFILING DATE:
January 8, 1999GROUP ART UNIT:
1623

U.S. PATENT DOCUMENTS

| EX. INIT | DOCU- MENT | DOCUMENT NUMBER | DATE | NAME |
|----------|---------------|-----------------|-----------|------------------|
| 4 | | 5,034,506 | July 1991 | Summerton et al. |
| | | | | |
| | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|---|---|---|
| 4 | • | Abrams et al., 1991, J. Immunol. 146:1455-1462 |
| 4 | • | Abrams et al., 1993, Cancer Res. 53:5501-5506 |
| 4 | • | Abrams et al., 1991, J. Invest. Dermatol. 96:31-37 |
| 4 | • | Alonso et al., 1996, Nature Med. 2:783-787 |
| 4 | • | Andersen et al., 1995, Neurology 45:1441-1445 |
| 4 | • | Appelt et al., 1996, J. Histochem. Cytochem. 44:1421-1427 |
| 4 | • | Barbas, 1995, Nature Medicine 1:837-839 |
| 4 | • | Bird et al., 1988, Science 242:423-426 |
| 4 | • | Blacker et al., 1997, Neurol. 48:139-147 |
| 4 | • | Bolton et al., 1993, Ann. Neurol. 33:94-100 |
| 4 | • | Branigan et al., 1996, Arthritis Rheumat. 39:1740-1746 |
| 4 | • | Breitner et al., 1994, Neurology 44:227-232 |
| 4 | • | Breteler et al., 1992, Epidemiol. Rev. 14:59-82 |
| 4 | • | Bretschneider et al., 1981, Am. J. Clin. Path. 76:450-453 |
| 4 | • | Burton and Barbas, 1994, Adv. Immunol. 57:191-280 |
| 4 | ✱ | Campbell et al., 1995, J. Infect. Dis. 172:585-588 |

EXAMINER

4 P. K. P. K.

DATE CONSIDERED

6-7-00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTORNEY DOCKET NO.:
10062-1APPLICATION NO.
09/227,749

INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)
(Use several sheets if necessary)APPLICANT:
Brian J. Balin, et al.FILING DATE:
January 8, 1999GROUP ART UNIT:
1623

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|---|--------------|--|
| 6 | • | Capron, 1996, Nature Med. 2:856-857 |
| 5 | • | Chakravarthy et al., 1995, Curr. Eye Res. 14:285-294 |
| 5 | • | Clark et al., 1993, Arch. Neurol. 50:1164-1172 |
| 5 | • | Connors et al., 1995, Stem Cells, 13:501-511 |
| 6 | • | Cook et al., 1996, Proc. Natl. Acad. Sci. USA 93:9223-9228 |
| 6 | • | Corder et al., 1993, Science 261:921-923 |
| 5 | • | de Kruif et al., 1995, J. Mol. Biol. 248:97-105 |
| 5 | • | Evans et al., 1989, J. Amer. Med. Assn. 262:2551-2556 |
| 5 | • | Friedland et al., Arch. Neurol. 47:177-178 |
| 5 | • | Gautrin et al., 1989, Can. J. Neurol. Sci. 16:375-387 |
| 5 | • | Gaydos et al., 1992, J. Clin. Microbiol. 30:796-800 |
| 5 | • | Gran et al., 1993, Scand. J. Rheumatol. 22:43-44 |
| 5 | • | Grayston et al., 1993, J. Infec. Dis. 168:1231-1235 |
| 5 | • | Grayston, 1992, Ann. Rev. Med. 43:317-323 |
| 5 | • | Grayston et al., 1990, J. Infect. Dis. 161:618-625 |
| 5 | • | Greenberg, 1990, Proc. Natl. Acad. Sci. USA 87:5827-5831 |
| 5 | • | Gu et al., 1997, Thrombosis and Hematocyst 77(4):755-759 |
| 5 | • | Hahn et al., 1991, J. Amer. Med. Assn. 266:225-230 |
| 5 | • | Hatch, 1998, Science 282:754-759 |
| 5 | • | Hixson et al., 1990, J. Lipid Res. 31:545-548 |
| | | |

EXAMINER

h. K. K.

DATE CONSIDERED

6-20

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | |
|--|--------------|--|-------------------------------|
| Form PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE (REV. 8-83) PATENT AND TRADEMARK OFFICE | | ATTORNEY DOCKET NO.: 10062-1 | APPLICATION NO. 09/227,749 |
| INFORMATION DISCLOSURE CITATION (Form PTO-1449 Modified 5/95) (Use several sheets if necessary) | | APPLICANT: Brian J. Balin, et al. | |
| | | FILING DATE: January 8, 1999 | GROUP ART UNIT: 1623 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 6 | * | Hofman et al., 1997, Lancet 349:151-153 | |
| 4 | g | Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883 | |
| 7 | o | Itzhaki et al., 1997, Lancet 349:241-244 | |
| 5 | r | Johnson, 1994, J. Neurol. Sci. 124:3-14 | |
| 4 | v | Keefover, 1996, Neurol. Clin. 14:337-351 | |
| 4 | o | Kingsbury et al., 1995, Mol. Brain Res. 28:311-318 | |
| 7 | * | Koskiniemi et al., 1996, Eur. Neurol. 36:160-163 | |
| 7 | * | Kurosaka et al., 1998, J. Immunol. 161:6245-6249 | |
| 7 | * | Lee et al., 1991, Science 251:675-679 | |
| 4 | o | Lee et al., 1996, J. Neurosci. 16:7513-7525 | |
| 4 | o | Leinonen, 1993, Eur. Heart J. 14:57-61 | |
| 4 | o | Lemere et al., 1996, Nature Med. 2:1146-1150 | |
| 4 | v | Li et al., 1998, Cell Biol. Int. 22:13-20 | |
| 6 | v | Li et al., 1996, Arthritis Rheumat. 39:950-958 | |
| 7 | o | Lippa et al., 1996, Neurol. 46:406-412 | |
| 4 | o | Löbau et al., 1995, Mol. Microbiol. 18:391-399 | |
| 4 | v | Lomax et al., 1990, Gene 86:209-216 | |
| 4 | * | Malinverni, 1996, Curr. Opin. Infect. Dis. 9:150-156 | |
| 6 | e | Mann et al., 1983, Acta Neurol. 60:24-28 | |
| 4 | - | Marks et al., 1991, J. Mol. Biol. 222:581-597 | |
| EXAMINER <i>h Kiah</i> | | | |
| DATE CONSIDERED <i>6/20</i> | | | |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | |

Form PTO-1449 (Modified)
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTORNEY DOCKET NO.:
10062-1APPLICATION NO.
09/227,749

INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)
(Use several sheets if necessary)APPLICANT:
Brian J. Balin, et al.FILING DATE:
January 8, 1999GROUP ART UNIT:
1623

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|---|--------------|---|
| 6 | • | McKee et al., 1991, Ann. Neurol. 30:156-165 |
| 7 | • | McKhann et al., 1984, Neurology 34:939-994 |
| 6 | • | Mehta et al., 1998, J. Infect. Dis. 177:1326-1331 |
| 5 | • | Melgosa et al., 1991, Infect. Immunol. 59:2195-2199 |
| 7 | • | Melgosa et al., 1994, Infect. Immun. 62:880-886 |
| 6 | • | Merrill et al., 1993, J. Immunol. 151:2132-2141 |
| 7 | • | Mirra et al., 1991, Neurology 41:479-486 |
| 6 | • | Miyashita et al., 1993, J. Med. Microbiol. 38:418-425 |
| 5 | • | Montarras et al., 1994, In: The Polymerase Chain Reaction, Mullis et al., eds., Birkhäuser Press, Boston, MA, pp. 277-294 |
| 6 | • | Muhlestein et al., 1996, J. Amer. Coll. Cardiol. 27:1555-1561 |
| 6 | • | Nielsen et al., 1991, Science 254:1497-1500 |
| 7 | • | Numazaki et al., 1995, J. Med. Microbiol. 42:191-195 |
| 6 | • | Peterson et al., 1998, Infect. Immun. 66:3848-3855 |
| 6 | • | Peterson et al., 1996, Infect. Immun. 64:3354-3359 |
| 7 | • | Pogo et al., 1987, Brain 110:907-915 |
| 6 | • | Poulakkainen et al., 1995, Microbiol. Immunol. 39:551-554 |
| 6 | • | Renvoize et al., 1987, Age and Ageing 16:311-314 |
| 7 | • | Rogers et al., 1993, Neurology 43:1609-1611 |
| 7 | • | Roses, 1996, Ann. Rev. Med. 47:387-400 |
| 7 | • | Schellenberg, 1995, Proc. Natl. Acad. Sci. USA 92:8552-8559 |
| 6 | • | Sriram et al., 1998, Neurol. 50:571-572 |

EXAMINER

L. Kihl

DATE CONSIDERED

6-7-00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 8-83) PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:
10062-1 (210062.0001)

APPLICATION NO.:
09/227,749

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)
(Use several sheets if necessary)

APPLICANT:
Brian J. Balin et al.

FILING DATE:
January 8, 1999

GROUP ART UNIT:
1623



MAY 12 2000

U.S. PATENT DOCUMENTS

| EX. INIT | DOCU - MENT | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
|-------------|-------------------|-----------------|------|------|-------|---------------|----------------------------------|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| EX. INIT | DOCU - MENT | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
|-------------|-------------------|-----------------|------|---------|-------|---------------|-----------------------|
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|---|--|---|
| 6 | | Jaruratanasirikul et al., March, 1996, "Distribution of Azithromycin Into Brain Tissue, Cerebrospinal Fluid, and Aqueous Humor of the Eye", <i>Antimicrobial Agents and Chemotherapy</i> , Vol 40, No. 3, p. 825-826. |
| 6 | | Matthews, 1986, <i>Neuropathology and Applied Neurobiology</i> 12:111-116 |
| 6 | | Morbidity and Mortality Weekly Report, CDC, 1993 Sexually Transmitted Diseases Treatment Guidelines, 42:No. RR-14 |
| | | |
| | | |
| | | |

EXAMINER E Peslev

DATE CONSIDERED

6-7-00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.